Skip to content

Motion Sickness on Astrolabe's Vessel

Evaluation and Characterization of Motion Sickness on Passengers Sailing on the Astrolabe

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02911402
Acronym
SICKVEST
Enrollment
147
Registered
2016-09-22
Start date
2014-10-31
Completion date
2018-12-31
Last updated
2022-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sea Sickness

Brief summary

Sea sickness syndrome is present for 80% of persons on board when the boat rotation missions Astrolabe, sometimes there is a risk of very significant dehydration. A special unit specialized in the fundamental study of the vestibular system (inner ear), sensory organ at the base of visual-vestibular conflict inducing this syndrome, also provides medical support for parabolic flights (flight reproducing weightlessness) where this syndrome is strongly present. The goal of the study is to assess the frequency of occurrence of this sea sickness syndrome on the Astrolabe, to understand the triggers (type of boat movements, personality traits, anxiety / stress) without changing habits on board for those on board taking a antinaupathique treatment given by the ship's doctor. This study will be done in collaboration between INSERM U 1075 (France) and the Laboratory of military research VIPER specialized in extreme environments (Belgium). The ultimate goal will be to provide the best recommendations and the best treatment regimen to alleviate as best as possible the symptoms of people on board of the Astrolabe so scientists on board can perform their work.

Detailed description

Background: The objectives were to assess the prevalence, severity, medication taken and to look for predictive factors, in order to better identify characteristics of passengers at risk of motion sickness during transport scientists travelling from Hobart in Tasmania to the French polar stations in Antarctica. Methods: Two hundred and thirty-nine passengers were surveyed over 4 years with 4 round trips per year using Motion Sickness Susceptibility Questionnaire (MSSQ), Simulator Sickness Questionnaire (SSQ), state-trait anxiety test (STAI-Trait and STAI-State), and general parameters (age, gender, number of trips, jet-lag, direction of the trip), medication, calculation of the distance of each passenger's cabin to the Centre of Gravity (CoG.).

Interventions

OTHERsea sickness questionnaires

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* participant aged of 18 or older but younger than 70 who received their medical ability to travel to Terre Adélie or making a research cruise aboard the Astrolabe * particpant signing the informed consent.

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Dietary intake surveyday 1 to day 10food intake
Motion Sickness susceptibilty questionnaire (fMSSQ)day 1 to day 10Sensitivity of motion sickness
STAY-YA questionnaireday 1 to day 10anxiety
STAY-YB questionnaireday 1 to day 10anxiety
Vis-Morgen Questonnaire about sleepingday 1 to day 10Subjective sleep scoring
Fatigue questionnaireday 1 to day 10Tiredness

Secondary

MeasureTime frameDescription
data from individual actigraphs worn by the participantsbaseline and every day up to 10 daysthis will allow to quantify particpant's movements related to the ship movement
personnality questionnaire (OCEAN)baseline and every day up to 10 daysPersonnality
anxiety questionnaire (STAY).baseline and every day up to 10 daysanxiety
treatment taken (international denomination and dose)baseline and every day up to 6 daystreatment taken by subject for motion sickness
type of movement from the ship using use the data from the Dynamic Positioning System on boardbaseline and every day up to 10 daysboat motion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026